news
Gilead submits drug application to FDA for HIV treatment
Gilead has submitted a new drug application to the US FDA for treatments of HIV.
List view / Grid view
Gilead Sciences
news
Gilead’s Phase II study showed 99% HCV cure rates
26 April 2017 | By Niamh Marriott, Junior Editor
Gilead Sciences’ Phase II studies demonstrated HCV cure rates of 99% in children, and 100% in patients co-infected with HCV and hepatitis B virus...
article
Gilead on HIV: New research, new treatments and the potential for a cure
15 March 2017 | By Mike Elliott, Vice President, Medical Affairs, Gilead Sciences
We caught up with Gilead’s Mike Elliott to find out the latest in HIV medication and whether a cure is finally within our reach…
article
The top 21… wealthiest pharma companies
European Pharmaceutical Review has been keeping the industry informed for 21 years and continues to bring insights into current and emerging technologies, contributions from recognised figures in the life science community and of course, the latest and most up to date news. To celebrate our success, we will be counting down…
news
EMA validates Gilead’s marketing application for their Hep C therapy
23 January 2017 | By Niamh Marriott, Digital Editor
The application is supported by data from two Phase 3 studies, which evaluated 12 weeks of the fixed-dose combination in antiviral-experienced patients...
news
GSK tops list ranking big pharma’s global access to medicine
14 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Read how the 2016 Access to Medicine Index ranks the top 20 pharmaceutical companies on their efforts to improve access to medicine in low- and middle-income countries...
news
PREVAIL IV – a trial to investigate if GS-5734 eliminates Ebola virus from semen
5 July 2016 | By Victoria White, Digital Content Producer
The six-month study will enrol 60 to 120 Ebola survivors whose semen has evidence of Ebola virus RNA prior to their enrolment...
news
FDA approves Epclusa for treatment of chronic HCV
29 June 2016 | By Victoria White, Digital Content Producer
Epclusa is the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection...
news
EC grants marketing authorisation to Odefsey in HIV
23 June 2016 | By Victoria White, Digital Content Producer
The EC has granted marketing authorisation for Gilead’s once-daily single tablet regimen Odefsey for the treatment of HIV-1 infection in certain patients...
news
Positive CHMP opinion for Gilead’s Epclusa in HCV
27 May 2016 | By Victoria White, Digital Content Producer
The EMA’s CHMP has adopted a positive opinion on Gilead’s Epclusa for the treatment of chronic hepatitis C virus...
news
EC grants marketing authorisation for two doses of Gilead’s Descovy
25 April 2016 | By Victoria White, Digital Content Producer
Descovy is the first new HIV backbone approved in Europe in more than a decade and represents an important advance in addressing the needs of patients...
news
Gilead announces results from two Phase III studies of TAF in HBV
15 April 2016 | By Victoria White, Digital Content Producer
Studies 108 and 110 were 48-week clinical trials evaluating TAF among 1,298 treatment-naïve and treatment-experienced patients with chronic HBV infection...
news
EMA to review Gilead’s Zydelig over safety concerns
14 March 2016 | By Victoria White
The European Medicines Agency's review follows concerns over serious adverse events in ongoing clinical trials of Zydelig (idelalisib)...
news
CHMP adopts positive opinion of Gilead’s Descovy
26 February 2016 | By Victoria White
Descovy is an investigational fixed-dose combination for the treatment of HIV-1 infection in adults and adolescents in combination with other HIV antiretroviral agents...
news
Gilead’s MAA for TAF in hepatitis B now under assessment by the EMA
26 February 2016 | By Victoria White
TAF is a novel, targeted prodrug of tenofovir that has demonstrated high antiviral efficacy similar to Gilead’s Viread at one-tenth of the dose...
